Ascendis Pharma A/S at JPMorgan Healthcare Conference Transcript
Great, good morning. Welcome everyone, I'm Jess Fye, a biotech analyst at JPMorgan. We're so excited to be starting the 44th Annual JPMorgan Healthcare Conference this week with Ascendis.
The company's CEO, Jan Mikkelsen, is going to give a presentation, that's going to be followed by some Q&A. But first, it looks like I'm going to pass it over to Scott Smith, the CFO, for a forward-looking statement.
/-
Thanks a lot, Jess. It's my honor to read the first FLS of the year for Ascendis Pharma. Before we begin, I would like to remind you that this conference call will contain forward-looking statements that are intended to be covered under the safe harbor provided by the Private Securities Litigation Reform Act.
Examples of such statements may include, but are not limited to, statements regarding our commercialization, continued development of SKYTROFA and YORVIPATH as well as
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
